Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

Lupin Appoints Dr. Kurt Nielsen as President of Lupin - Somerset

Mumbai, April 05, 2016: Pharma major Lupin, today, announced the appointment of Dr. Kurt Nielsen as President of Lupin – Somerset. Kurt will be responsible for overall operations of the Gavis-Novel Somerset business and will be based out of Somerset, New Jersey. With the successful closure / completion of the Gavis acquisition earlier this month, Lupin now has the 5th largest ANDA pipeline pending approval with the US FDA putting it in a formidable position in the US, making this role critical to the overall growth and expansion of the company.

An accomplished pharmaceutical executive, Kurt has over 20 years of rich experience in creating, managing high growth businesses; research, development and launching new products in the US; managing transactions, business development and Mergers & Acquisitions. Kurt joins Lupin from Sandoz, where he held dual responsibility of being the Global Head of Product Development (a.i.) as well as being the Vice-President of US Product Development, Portfolio and Launch Management for generic and brand products. Having started his pharmaceutical career at Johnson & Johnson, Kurt's previous leadership roles include being the Chief Technology Officer & Senior Vice-President at Catalent Pharma Solutions, responsible for their global R&D efforts; Senior Vice President in-charge of R&D, Technology ops. including Manufacturing & Quality at URL Mutual Pharmaceuticals and being the Executive Director of Generic R&D at TEVA Pharmaceuticals. He holds a Ph.D in Chemistry from the Villanova University and has a BS in Chemistry from the University of Delaware.

Commenting on the appointment, Ms. Vinita Gupta, CEO, Lupin Limited said, *"Kurt joins us at an exciting phase of Lupin's evolution as a Global Generics powerhouse and an emerging Specialty Pharmaceutical company, having closed the Gavis acquisition recently. We have ambitious plans to further strengthen and expand our generic as well as specialty business in the US. I am confident that Kurt's leadership, knowledge and rich experience will help accelerate growth momentum and meet and exceed the ambitious targets that we have set for ourselves. We are delighted to have Kurt join the Lupin family."*

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th – IMS Health). For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively. Please visit http://www.lupin.com for more information.

You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPC IN

For further information or queries, please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupin.com

or

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupin.com

Safe Harbor Statement